ESMO guidelines: Interim update on new targeted therapies for CLL

The European Society for Medical Oncology (ESMO) has released an interim update to their clinical practice guidelines for chronic lymphocytic leukemia (CLL). This update includes new recommendations for targeted therapies for the treatment of first line (1L) and relapsed/refractory (R/R) CLL.

In the ESMO interim update, the treatment algorithms for first line and relapsed therapy for CLL have been updated.

Key amendments to the guidelines cover:

• The approval of time-limited ibrutinib plus venetoclax in the first-line setting.
• New data on minimal residual disease-driven treatment.
• The approval of zanubrutinib for treating both first-line and R/R CLL.
• The additional evidence on time-limited venetoclax plus anti-CD20 antibody combination in the first line.
• Insights on later-line treatments, depending on preceding treatment.

These updates aim to improve patient outcomes by incorporating the latest evidence and treatment options for CLL and aim to help HCPs to tailor therapy based on patient characteristics and response.